Cancer
|

The impact of microRNA-146a on the development of immune related adverse events during immune checkpoint inhibitor therapy

Institution: Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center – University of Freiburg
Applicant: Natalie Köhler
Funding line:
First and Second Applications
Image: Analysis
TaqMan-based analysis of a single nucleotide polymorphism in the miR-146a gene
(© Medical Center – University of Freiburg, Natalie Köhler)

With the development of immune checkpoint inhibitors, the treatment landscape of numerous cancer entities has been revolutionized. However, severe immune-related adverse events (irAEs) can occur, which oftentimes require ICI discontinuation and corticosteroid treatment, hence limiting the success of ICI therapy. In our project, we aim to analyze the pathomechanisms of irAE development with a focus on the immunoregulatory microRNA miR-146a. Moreover, we want to identify and examine further potentially involved microRNAs. We thereby aim to identify new molecular targets and establish novel biomarkers to predict irAE development.

Here you can get further information.